22-October-2018: The global cell harvesting system market is anticipated to touch a valuation of USD 10.17 billion by 2025, as per a report by Grand View Research, Inc. Cell harvesting systems are medical devices which acquire stem cells with high accuracy without causing cell replenishment to the donor. Stem cells are collected using three major methods – peripheral blood, umbilical blood, and bone marrow. These cells are characterized by their ability to regenerate tissue and are tested with the help of clonogenic assays.
Autologous stem cell transplantation or autotransplantation is a method of transplanting tissues and organs from one part of the body to the other. This method has high scope for treating severe injuries and third-degree burns with autografting. For instance, the ReCell device by Avita Medical was precisely designed for autotransplantation purposes. In April 2015, the company received the CE Mark clearance for an advanced version of the device to create skin cells which can be used in treating a larger surface area (1920 cm2) of the body.
Autologous stem cell transplantation or autotransplantation is a method of transplanting tissues and organs from one part of the body to the other. This method has high scope for treating severe injuries and third-degree burns with autografting. For instance, the ReCell device by Avita Medical was precisely designed for autotransplantation purposes. In April 2015, the company received the CE Mark clearance for an advanced version of the device to create skin cells which can be used in treating a larger surface area (1920 cm2) of the body.
The inability to harvest sufficient stem cells by some patients has led to the emergence of stem cell mobilization therapy. Plerixafor (branded as Mozobil in the U.S.), an immunostimulant drug, has been highly effective in mobilizing stem cells for harvesting after previous unsuccessful attempts. In a cohort conducted on Japanese patients in October 2017, the drug was highly effective in collecting hematopoietic stem cells (HSCs) for patients suffering from multiple myeloma.
The cell harvesting system market is expected to exhibit a 13.9% CAGR from 2014 to 2025 (forecast period) due to high usage of cell harvesting in stem cell research. High prevalence of blood-related disorders and growing geriatric populace are factors anticipated to propel demand during the forecast period. Developments in stem cell banking and autologous stem cell transplantation are projected to propel market growth due to use of stem cells in regenerative medicine. Prominent industry participants include PerkinElmer, Inc.; Avita Medical; Terumo Corporation; and Bertin Technologies.
In-Depth Research Report On Cell Harvesting System Market:
https://www.grandviewresearch.com/industry-analysis/cell-harvesting-systems-market
No comments:
Post a Comment